Abstract: A therapeutic method of alleviating the symptoms of failed back surgery syndrome, post laminectomy syndrome, post-surgery syndrome, sympathetic dystrophies, macular degenerations, complex regional pain syndrome, reflex sympathetic dystrophy and neuropathies by administering to the afflicted subject a therapeutically effective amount of cetyl myristoleate alone, or in combination with selective effective amount of aspirin, gabapentin, pregabalin, duloxetine, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, neuroceuticals, Neurontin, Cymbalta, Lyrica, muscle relaxers, anti-depressants, nortriptyline, local anesthetics, and steroids.

Abstract: The present invention presents a medical instrument for penetrating cutaneous and sub-cutaneous tissue, causing less hemorrhage and patient pain. This medical device for insertion into tissue comprising one or more section, said section including a plurality of facets; and each facet is configured to deflect the tissue it contacts in a direction that is different than adjacent facets.

Abstract: Methods, apparatus, compositions and kits for inhibiting a disorder in a human patient, including non-cerebral neurovascular disorder or muscular headache pain, or loss of motor or sensory function, sympathetic tone or range or fluidity of motion that affect a nerve pathway at more than one locus associated with the disorder to inhibit the disorder. Alternatively or in addition, neuropathy associated with a disorder is treatable by palpating to determine a Keystone nerve essential to the neuropathy, applying pressure to determine a point of maximum discomfort or trigger of increased symptoms to identify a Levin Sign as a locus of initial intervention, and intervening to treat the neuropathy at the location of the Levin Sign by administering a pharmaceutically active agent, internal implanted or external neuro stimulation affecting the nerve pathway to inhibit the neuropathy.

Abstract: A drug delivery system includes flexible and interchangeable nozzle and tip. In one embodiment, the present invention relates to a medical device for intranasal delivery of a medicament. The present invention effectively delivers an appropriate amount of medicament to the designated surface area. In one other embodiment., the present invention ensures that a complete dosage of the medicament is delivered, especially to specific areas in the nasal cavity such as the rear of the nasal cavity where the SPG is located.

Abstract: The present invention relates to a medical device for intranasal delivery of a medicament. The medicament may be any type of medicament suitable for nasal administration and delivery in the form of a spray. The present invention ensures that a complete dosage of the medicament is delivered, especially to specific areas in the nasal cavity, such as the rear of the nasal cavity where the SPG is located.

Abstract: A system for tracking one or more drugs comprising a central database adapted to track a drug through its lifecycle from point of manufacture to use by a patient. The system is further adapted to recognize inconsistencies or patterns indicating illicit or improper use of a drug.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The apparatus includes an electronic neural stimulator capable of stimulating a dorsonasal nerve structure associated with pain in a subject, thereby inhibiting the pain, and includes a power supply for providing the neural stimulation; and at least one electrical conduit coupled between the power supply and a dorsonasal nerve structure associated with the cerebral neurovascular disorder in a manner to transmit the neural stimulation to the dorsonasal nerve structure associated with the pain to thereby inhibit the pain. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches.

Abstract: The disclosure relates to the discovery that certain cerebrovascular disorders in humans who exhibit seemingly normal intracranial pressure (ICP) and do not exhibit hydrocephalus can be alleviated or prevented by reducing ICP in the human. Disorders of this type are herein designated normotensive, nonhydrocephalus tenso-responsive cerebrovascular disorder (NNTCDs). The disclosure describes methods of relieving head pain and other symptoms of NNTCDs, for example by withdrawing cerebrospinal fluid (CSF) from the subarachnoid space of a human or by administering a pharmaceutical agent that modulates CSF production, uptake, or both. Methods of assessing whether a human is afflicted with one or more NNTCDs are also described. The disclosure describes numerous pharmaceutical compositions suitable for administration to humans afflicted with NNTCDs to alleviate or prevent such disorders. Such compositions can, for example, include both a CSF-reducing agent and a symptomatic (e.g., head pain) relief agent.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The apparatus includes an electronic neural stimulator capable of stimulating a dorsonasal nerve structure associated with pain in a subject, thereby inhibiting the pain, and includes a power supply for providing the neural stimulation; and at least one electrical conduit coupled between the power supply and a dorsonasal nerve structure associated with the cerebral neurovascular disorder in a manner to transmit the neural stimulation to the dorsonasal nerve structure associated with the pain to thereby inhibit the pain. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches.

Abstract: Methods, apparatus, compositions and kits for inhibiting a disorder in a human patient, including non-cerebral neurovascular disorder or muscular headache pain, or loss of motor or sensory function, sympathetic tone or range or fluidity of motion that affect a nerve pathway at more than one locus associated with the disorder to inhibit the disorder. Alternatively or in addition, neuropathy associated with a disorder is treatable by palpating to determine a Keystone nerve essential to the neuropathy, applying pressure to determine a point of maximum discomfort or trigger of increased symptoms to identify a Levin Sign as a locus of initial intervention, and intervening to treat the neuropathy at the location of the Levin Sign by administering a pharmaceutically active agent, internal implanted or external neuro stimulation affecting the nerve pathway to inhibit the neuropathy.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The apparatus includes an electronic neural stimulator capable of stimulating a dorsonasal nerve structure associated with pain in a subject, thereby inhibiting the pain, and includes a power supply for providing the neural stimulation; and at least one electrical conduit coupled between the power supply and a dorsonasal nerve structure associated with the cerebral neurovascular disorder in a manner to transmit the neural stimulation to the dorsonasal nerve structure associated with the pain to thereby inhibit the pain. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The apparatus includes an electronic neural stimulator capable of stimulating a dorsonasal nerve structure associated with pain in a subject, thereby inhibiting the pain, and includes a power supply for providing the neural stimulation; and at least one electrical conduit coupled between the power supply and a dorsonasal nerve structure associated with the cerebral neurovascular disorder in a manner to transmit the neural stimulation to the dorsonasal nerve structure associated with the pain to thereby inhibit the pain. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceutically active agent to an animal are also included in the invention.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceutically active agent to an animal are also included in the invention.

Abstract: The disclosure relates to the discovery that certain cerebrovascular disorders in humans who exhibit seemingly normal intracranial pressure (ICP) and do not exhibit hydrocephalus can be alleviated or prevented by reducing ICP in the human. Disorders of this type are herein designated normotensive, nonhydrocephalus tenso-responsive cerebrovascular disorder (NNTCDs). The disclosure describes methods of relieving head pain and other symptoms of NNTCDs, for example by withdrawing cerebrospinal fluid (CSF) from the subarachnoid space of a human or by administering a pharmaceutical agent that modulates CSF production, uptake, or both. Methods of assessing whether a human is afflicted with one or more NNTCDs are also described. The disclosure describes numerous pharmaceutical compositions suitable for administration to humans afflicted with NNTCDs to alleviate or prevent such disorders. Such compositions can, for example, include both a CSF-reducing agent and a symptomatic (e.g., head pain) relief agent.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceutically active agent to an animal are also included in the invention.

Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceutically active agent to an animal are also included in the invention.

Abstract: The invention relates generally to the field of treatment of headache, post-laminectomy syndrome, and other disorders associated with localized pain. The compositions and methods described herein are useful for alleviating both the disorders and the pain associated therewith.

Abstract: A system and method of tracking medical products provides for associating a group of medical products with a group location based on a group radio frequency identification (RF ID) device signal, where the group includes a first unit a second unit. The first unit is associated with a first remote location based on a first unit RE ID device signal. The method further provides for associating the second unit with a second remote location based on a second unit RE ID device signal. The signals uniquely identify the units and the group.

Abstract: A system and method of tracking medical products provides for associating a group of medical products with a group location based on a group radio frequency identification (RF ID) device signal, where the group includes a first unit and a second unit. The first unit is associated with a first remote location based on a first unit RF ID device signal. The method further provides for associating the second unit with a second remote location based on a second remote location based on a second unit RF ID device signal. The signals uniquely identify the units and the group.